2 Brade KD, Rybak JM, Rybak MJ. Oritavancin: A new lipoglycopeptide antibiotic in the treatment of gram-positive infections. Infect Dis Ther. 2016;5(1):1–15.
21 Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254–62.
26 Redell M, Sierra-Hoffman M, Assi M, Bochan M, Chansolme D, Gandhi A, et al. The CHROME study, a real-world experience of single- and multiple-dose Oritavancin for treatment of gram-positive infections. Open Forum Infect Dis. 2019;6(11):ofz479.
30 Stewart CL, Turner MS, Frens JJ, Snider CB, Smith JR. Real-world experience with Oritavancin therapy in invasive gram-positive infections. Infect Dis Ther. 2017;6(2): 277–89.
39 Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O’Riordan W. Single intravenous dose of Oritavancin for treatment of acute skin and skin structure infections caused by gram-positive bacteria: Summary of safety analysis from the phase 3 SOLO studies. Antimicrob Agents Chemother. 2018;62(4):e01919–17.
1. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54(Suppl 3):S214–9.
2. Brade KD, Rybak JM, Rybak MJ. Oritavancin: A new lipoglycopeptide antibiotic in the treatment of gram-positive infections. Infect Dis Ther. 2016;5(1):1–15.
3. Saravolatz LD, Stein GE. Oritavancin: A long-half-life lipoglycopeptide. Clin Infect Dis. 2015;61(4):627–32.
4. Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS, Jones RN. Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. J Glob Antimicrob Resist. 2017;8:28–32.
5. Sweeney D, Shinabarger DL, Arhin FF, Belley A, Moeck G, Pillar CM. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 2017;87(2):121–8.
6. Pfaller MA, Sader HS, Flamm RK, Castanheira M, Mendes RE. Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010–2014. Diagn Microbiol Infect Dis. 2018;91(2):199–204.
7. Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS, Jones RN. Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin in vitro potency. J Antimicrob Chemother. 2016;71(12):3453–8.
8. Sweeney D, Stoneburner A, Shinabarger DL, Arhin FF, Belley A, Moeck G, Pillar CM. Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci. J Antimicrob Chemother. 2017;72(2):622–4.
9. Mendes RE, Sader HS, Castanheira M, Flamm RK. Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010–2016): concomitant analysis of oritavancin in vitro activity. J Chemother. 2018;30(5):280–9.
10. Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis. 2012;54(Suppl 3):S203–13.
11. Mendes RE, Farrell DJ, Sader HS, Flamm RK, Jones RN. Oritavancin activity tested against molecularly characterized Staphylococci and Enterococci displaying elevated linezolid MIC results. Antimicrob Agents Chemother. 2016;60(6):3817–20.
12. Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 2003;47(5):1700–6.
13. Rose WE, Hutson PR. A two-dose Oritavancin regimen using pharmacokinetic estimation analysis. Drugs Real World Outcomes. 2020;7(Suppl 1):36–40.
14. Baquir B, Lemaire S, Van Bambeke F, Tulkens PM, Lin L, Spellberg B. Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin. Clin Infect Dis. 2012;54(Suppl 3):S229–32.
15. Zelmer AR, Nelson R, Richter K, Atkins GJ. Can intracellular Staphylococcus aureus in osteomyelitis be treated using current antibiotics? A systematic review and narrative synthesis. Bone Res. 2022;10(1):53.
16. Lehoux D, Ostiguy V, Cadieux C, Malouin M, Belanger O, Far AR, Parr TR Jr. Oritavancin pharmacokinetics and bone penetration in rabbits. Antimicrob Agents Chemother. 2015;59(10):6501–5.
17. Belley A, Lalonde Seguin D, Arhin F, Moeck G. Comparative in vitro activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-resistant Staphylococcus aureus isolates in a nondividing state. Antimicrob Agents Chemother. 2016;60(7):4342–5.
18. Yan Q, Karau MJ, Patel R. In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci. Diagn Microbiol Infect Dis. 2018;91(4):348–50.
19. Dunbar LM, Milata J, McClure T, Wasilewski MM. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011;55(7):3476–84.
20. Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180–90.
21. Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254–62.
22. Saddler K, Zhang J, Sul J, Patel P, Castro-Lainez M, Stevens ML, et al. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital. PLoS One, 2021;16(3):e0248129.
23. Anastasio PJ, Wolthoff P, Galli A, Fan W. Single-dose Oritavancin compared to standard of care IV antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: A retrospective real-world study. Infect Dis Ther. 2017;6(1):115–28.
24. Schulz LT, Dworkin E, Dela-Pena J, Rose WE. Multiple-dose Oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy. 2018;38(1):152–9.
25. Redell M, Moeck G, Lucasti C, Durso S, Kennedy C, Fusaro K, et al. A real-world patient registry for Oritavancin demonstrates efficacy and safety consistent with the phase 3 SOLO program. Open Forum Infect Dis. 2018;5(6):ofy051.
26. Redell M, Sierra-Hoffman M, Assi M, Bochan M, Chansolme D, Gandhi A, et al. The CHROME study, a real-world experience of single- and multiple-dose Oritavancin for treatment of gram-positive infections. Open Forum Infect Dis. 2019;6(11):ofz479.
27. Lodise TP, Palazzolo C, Reksc K, Packnett E, Redell M. Comparisons of 30-day admission and 30-day total healthcare costs between patients who were treated with Oritavancin or Vancomycin for a skin infection in the outpatient setting. Open Forum Infect Dis. 2019;6(12):ofz475.
28. Van Hise NW, Chundi V, Didwania V, Anderson M, McKinsey D, Roig I, et al. Treatment of acute osteomyelitis with once-weekly Oritavancin: A two-year, multicenter, retrospective study. Drugs Real World Outcomes. 2020;7(Suppl 1):41–5.
29. Ahiskali A, Rhodes H. Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs. BMC Pharmacol Toxicol. 2020;21(1):73.
30. Stewart CL, Turner MS, Frens JJ, Snider CB, Smith JR. Real-world experience with Oritavancin therapy in invasive gram-positive infections. Infect Dis Ther. 2017;6(2): 277–89.
31. Dretske D, Schulz L, Werner E, Sharp B, Pulia M. Effectiveness of oritavancin for management of skin and soft tissue infections in the emergency department: A case series. Am J Emerg Med. 2021;43:77–80.
32. Chastain DB, Davis A. Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review. Int J Antimicrob Agents. 2019;53(4):429–34.
33. Johnson JA, Feeney ER, Kubiak DW, Corey GR. Prolonged use of Oritavancin for Vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis. Open Forum Infect Dis. 2015;2(4):ofv156.
34. Antony SJ, Cooper LG. Use of Oritavancin (novel new lipoglycopeptide) in the treatment of prosthetic joint infections (PJI): A possible alternative novel approach to a difficult problem. Infect Disord Drug Targets. 2017;17(2):77–80.
35. Delaportas DJ, Estrada SJ, Darmelio M. Successful treatment of Methicillin susceptible Staphylococcus aureus osteomyelitis with Oritavancin. Pharmacotherapy. 2017;37(8):e90–e2.
36. Dahesh S, Wong B, Nizet V, Sakoulas G, Tran TT, Aitken SL. Treatment of multidrug-resistant Vancomycin-resistant Enterococcus faecium hardware-associated vertebral osteomyelitis with Oritavancin plus Ampicillin. Antimicrob Agents Chemother. 2019;63(7): e02622–18.
37. Nguyen JP, Contreras BX, Sierra-Hoffman M, Saddler K, Stevens ML, Castro-Lainez MT, et al. Successful treatment of a prosthetic hip infection due to Enterococcus faecalis with sequential dosing of oritavancin and prosthesis preservation without prosthetic joint surgical manipulation. IDCases. 2020;22:e00949.
38. Compendium.ch. [Internet]. Bern: HCI Solutions AG; c2023 [letzter Aufruf am 15.11.2022]. Tenkasi. Verfügbar unter: https://www.compendium.ch/product/1508548-tenkasi-trockensub-400-mg.
39. Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O’Riordan W. Single intravenous dose of Oritavancin for treatment of acute skin and skin structure infections caused by gram-positive bacteria: Summary of safety analysis from the phase 3 SOLO studies. Antimicrob Agents Chemother. 2018;62(4):e01919–17.
40. Belley A, Robson R, Francis JL Belley A, Robson R, Francis JL, Adcock DM, et al. Effects of Oritavancin on coagulation tests in the clinical laboratory. Antimicrob Agents Chemother. 2017;61(2): e01968–16.
41. Dellsperger S, Kramer S, Stoller M, Burger A, Geissbühler E, Amsler I, et al. Early switch from intravenous to oral antibiotics in skin and soft tissue infections: An algorithm-based prospective multicenter pilot trial. Open Forum Infect Dis. 2022;9(7):ofac197.
42. Olearo F, Albrich WC, Vernaz N, Harbarth S, Kronenberg A. Staphylococcus aureus and Methicillin resistance in Switzerland: regional differences and trends from 2004 to 2014. Swiss Med Wkly. 2016;146:w14339.
43. Renggli L, Gasser M, Buetti N, Kronenberg A, Hg. The increase in methicillin-susceptible Staphylococcus aureus bacteraemia in Switzerland (2008–2021) is mainly driven by elderly male of the German-speaking part [Internet]. Bern: Anresis; 2022 [letzter Aufruf am 15.11.2022]. Verfügbar unter: https://www.anresis.ch/wp-content/uploads/2022/08/202208_SAB_Renggli.pdf.
44. Roth JA, Hornung-Winter C, Radicke I, Hug BL, Biedert M, Abshagen C, et al. Direct costs of a contact isolation day: A prospective cost analysis at a Swiss university hospital. Infect Control Hosp Epidemiol. 2018;39(1):101–3.
45. Jensen IS, Wu E, Fan W, Lodise TP, Nicolau DP, Dufour S, et al. Use of Oritavancin in moderate-to-severe ABSSSI patients requiring IV antibiotics: A U.S. payer budget impact analysis. J Manag Care Spec Pharm. 2016;22(6):752–64.
46. Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, et al. Use of Oritavancin in acute bacterial skin and skin structure infections patients receiving intravenous antibiotics: A US hospital budget impact analysis. Clin Drug Investig. 2016;36(2):157–68.
47. Lodise TP, Fan W, Sulham KA. Economic impact of Oritavancin for the treatment of acute bacterial skin and skin structure infections in the emergency department or observation setting: Cost savings associated with avoidable hospitalizations. Clin Ther. 2016; 38(1):136–48.
48. Agarwal R, Bartsch SM, Kelly BJ, Prewitt M, Liu Y, Chen Y, Umscheid CA. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018;24(4):361–8.
49. Brownell LE, Adamsick ML, McCreary EK, Vanderloo JP, Ernst EJ, Jackson ER, Schulz LT. Clinical outcomes and economic impact of Oritavancin for gram-positive infections: A single academic medical center health system experience. Drugs Real World Outcomes. 2020;7(Suppl 1):13–9.
50. Williams B, Muklewicz J, Steuber TD, Williams A, Edwards J. Comparison of inpatient standard-of-care to outpatient Oritavancin therapy for patients with acute uncomplicated cellulitis. J Pharm Pract. 2021:8971900211021258.
51. Zinzi D, Vlachaki I, Falla E, Mantopoulos T, Nathwani D. Cost-minimisation analysis of Oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective. Eur J Health Econ. 2022;23(8):1371–81.
52. Swissmedic [Internet]. Bern: Swissmedic; c2019 [letzter Aufruf am 15.11.2022]. Tenkasi®, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung (Oritavancinum). Verfügbar unter: https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/tenkasi-pulver-infusionsloesung-oritavancinum.html.
53. Klinker KP, Borgert SJ. Beyond Vancomycin: The tail of the lipoglycopeptides. Clin Ther. 2015;37(12):2619–36.